全文获取类型
收费全文 | 2222篇 |
免费 | 255篇 |
国内免费 | 1篇 |
专业分类
耳鼻咽喉 | 28篇 |
儿科学 | 68篇 |
妇产科学 | 41篇 |
基础医学 | 376篇 |
口腔科学 | 108篇 |
临床医学 | 265篇 |
内科学 | 496篇 |
皮肤病学 | 46篇 |
神经病学 | 209篇 |
特种医学 | 73篇 |
外科学 | 300篇 |
综合类 | 8篇 |
一般理论 | 3篇 |
预防医学 | 182篇 |
眼科学 | 36篇 |
药学 | 143篇 |
中国医学 | 2篇 |
肿瘤学 | 94篇 |
出版年
2023年 | 37篇 |
2022年 | 10篇 |
2021年 | 39篇 |
2020年 | 45篇 |
2019年 | 49篇 |
2018年 | 81篇 |
2017年 | 88篇 |
2016年 | 87篇 |
2015年 | 107篇 |
2014年 | 99篇 |
2013年 | 211篇 |
2012年 | 150篇 |
2011年 | 136篇 |
2010年 | 101篇 |
2009年 | 46篇 |
2008年 | 82篇 |
2007年 | 89篇 |
2006年 | 90篇 |
2005年 | 75篇 |
2004年 | 104篇 |
2003年 | 70篇 |
2002年 | 75篇 |
2001年 | 25篇 |
1999年 | 14篇 |
1998年 | 15篇 |
1997年 | 11篇 |
1996年 | 17篇 |
1995年 | 21篇 |
1992年 | 17篇 |
1991年 | 17篇 |
1989年 | 11篇 |
1988年 | 12篇 |
1987年 | 16篇 |
1986年 | 21篇 |
1985年 | 15篇 |
1984年 | 22篇 |
1982年 | 16篇 |
1981年 | 12篇 |
1980年 | 10篇 |
1979年 | 14篇 |
1978年 | 10篇 |
1977年 | 10篇 |
1976年 | 10篇 |
1975年 | 9篇 |
1974年 | 10篇 |
1955年 | 38篇 |
1954年 | 88篇 |
1949年 | 20篇 |
1948年 | 17篇 |
1943年 | 11篇 |
排序方式: 共有2478条查询结果,搜索用时 15 毫秒
71.
We evaluated weight changes in obese patients at 6‐months after they ended participation in a 12‐month randomised controlled trial in which they received daily placebo, zonisamide 200 mg or zonisamide 400 mg, in addition to lifestyle counselling. Of the originally randomised 225 patients, 218 completed month‐12 when study interventions were discontinued. For the 154 patients who returned for 6‐month follow‐up off‐treatment, weight changes between month‐12 and month‐18 for placebo (n = 53), zonisamide 200 mg (n = 49) and zonisamide 400 mg groups (n = 52) were 0.5 kg [95% confidence interval (CI), ?0.8 to 1.8; 0.7%], 1.5 kg (0.2–2.8; 1.6%; p = 0.26 vs. placebo) and 2.4 kg (1.1–3.7; 2.6%; p = 0.04 vs. placebo), respectively. Our results suggest that although zonisamide 400 mg daily for 12‐months resulted in greater weight loss than with placebo, weight regain after discontinuation of interventions was greater in the zonisamide 400 mg group than placebo group. 相似文献
72.
73.
74.
Willingham SB Volkmer JP Gentles AJ Sahoo D Dalerba P Mitra SS Wang J Contreras-Trujillo H Martin R Cohen JD Lovelace P Scheeren FA Chao MP Weiskopf K Tang C Volkmer AK Naik TJ Storm TA Mosley AR Edris B Schmid SM Sun CK Chua MS Murillo O Rajendran P Cha AC Chin RK Kim D Adorno M Raveh T Tseng D Jaiswal S Enger PØ Steinberg GK Li G So SK Majeti R Harsh GR van de Rijn M Teng NN Sunwoo JB Alizadeh AA Clarke MF Weissman IL 《Proceedings of the National Academy of Sciences of the United States of America》2012,109(17):6662-6667
CD47, a "don't eat me" signal for phagocytic cells, is expressed on the surface of all human solid tumor cells. Analysis of patient tumor and matched adjacent normal (nontumor) tissue revealed that CD47 is overexpressed on cancer cells. CD47 mRNA expression levels correlated with a decreased probability of survival for multiple types of cancer. CD47 is a ligand for SIRPα, a protein expressed on macrophages and dendritic cells. In vitro, blockade of CD47 signaling using targeted monoclonal antibodies enabled macrophage phagocytosis of tumor cells that were otherwise protected. Administration of anti-CD47 antibodies inhibited tumor growth in orthotopic immunodeficient mouse xenotransplantation models established with patient tumor cells and increased the survival of the mice over time. Anti-CD47 antibody therapy initiated on larger tumors inhibited tumor growth and prevented or treated metastasis, but initiation of the therapy on smaller tumors was potentially curative. The safety and efficacy of targeting CD47 was further tested and validated in immune competent hosts using an orthotopic mouse breast cancer model. These results suggest all human solid tumor cells require CD47 expression to suppress phagocytic innate immune surveillance and elimination. These data, taken together with similar findings with other human neoplasms, show that CD47 is a commonly expressed molecule on all cancers, its function to block phagocytosis is known, and blockade of its function leads to tumor cell phagocytosis and elimination. CD47 is therefore a validated target for cancer therapies. 相似文献
75.
Jianu CS Lange OJ Viset T Qvigstad G Martinsen TC Fougner R Kleveland PM Fossmark R Hauso Ø Waldum HL 《Scandinavian journal of gastroenterology》2012,47(1):64-67
We present a case of a gastric neuroendocrine carcinoma in a patient with a history of long-term proton pump inhibitor (PPI) use. A 49-year-old man using PPI for the last 15 years due to gastroesophageal reflux disease developed progressive dysphagia, dyspepsia and weight loss. Upper gastrointestinal endoscopy, endoscopic ultrasonography and abdominal CT diagnosed a malignant tumor localized to a hiatal hernia. Fasting serum chromogranin A and gastrin concentrations were elevated (32 nmol/l and 159 pmol/l, respectively). Helicobacter pylori PCR analysis of antral biopsies was negative. Biopsies from endoscopically normal oxyntic mucosa showed enterochromaffin-like (ECL) cell hyperplasia. Tumor biopsies revealed a poorly differentiated neuroendocrine carcinoma. Sevier-Munger staining, immunohistochemistry and electron microscopy indicated ECL cell as origin of the tumor cells. Concerns have previously been raised about the safety of long-term PPI use due to a possible increased risk of cancer. This case illustrates a patient with a poorly differentiated neuroendocrine carcinoma with ECL cell characteristics probably induced by hypergastrinemia secondary to long-term PPI use. 相似文献
76.
77.
78.
79.
80.